The strength of this research is its clinically relevant emphasis on CKD patients secondary to two of the world’s most prevalent comorbidities, diabetes and hypertension and its concurrent comparison of BNP and NT-proBNP by CKD stage. This evidence concerns the gene NPPB and hypertensive disorder.